Glaxo receives FDA 'complete response' for cervical cancer vaccine
Dec 17 2007 - 8:24am
GlaxoSmithKline (NYSE: GSK) announced today that it has received a complete response letter from the U.S. Food and Drug Administration related to its application for the cervical cancer vaccine, CERVARIX
Share this content.
Contact Us To Be Mentioned in EmaxHealth.com
Please include eMaxHealth in Google Alerts to receive tomorrow's stories and SHARE this with friends if it was interesting.
AdvertisementReporter and Bloggers, Write for EmaxHealth and Get Paid. Click to Contact Us For Details